Pharmaceutical Supply Chain Disruption: Regional Impact Analysis Global pharmaceutical price volatility correlates directly with geopolitical instability in production regions. Iran sanctions (2018-present) reduced key active pharmaceutical ingredient (API) suppliers by approximately 8-12% of European market availability, forcing UK and EU nations to source from alternative suppliers at 15-40% premium costs. Croatia's healthcare system, dependent on imported generics for 65% of medication supply, faces identical pressure—domestic production capacity covers only 35% of demand compared to 55% in 2008. This structural vulnerability explains cascading price increases across Central Europe and underscores why pharmaceutical supply chain resilience has become a critical national security infrastructure priority for mid-sized economies.